Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.34 USD | -5.24% | +2.36% | +17.41% |
09/05 | NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
08/05 | Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.41% | 2.13Cr | |
+9.99% | 12TCr | |
+12.01% | 11TCr | |
-3.07% | 2.47TCr | |
-0.93% | 2.2TCr | |
-5.43% | 1.93TCr | |
-6.90% | 1.76TCr | |
-39.36% | 1.73TCr | |
+5.82% | 1.4TCr | |
+33.05% | 1.21TCr |
- Stock Market
- Equities
- NRBO Stock
- News NeuroBo Pharmaceuticals, Inc.
- NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise